Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QUILT-2.013 A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer

NCT00791154 is registered in ClinicalTrials.gov with NantCell, Inc. as lead sponsor.

NCT NCT00791154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00791154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QUILT-2.013 A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer
Lead sponsor
NantCell, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
December 2, 2008
Completion date
May 1, 2013
Enrollment
213 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small cell lung cancer, lung cancer, small cell lung cancer, solid tumors